Dubai, UAE - The Emirates Drug Authority announced the approval of the drug “ EURneffy® ”, which contains the active ingredient epinephrine, in concentrations of 1 and 2 mg, making the UAE the first in the region to approve this product as the first nasal adrenaline spray intended for the emergency treatment of severe hypersensitivity reactions in adults and children aged four years and above. The dose is determined based on the patient’s weight.

This product, developed by ALK Abelló , represents a qualitative addition to the country’s healthcare and pharmaceutical system, by making it possible to administer treatment via the nose as an innovative alternative to injections, thus enhancing the speed of response in dealing with acute allergy attacks. This approach is of particular importance, as administering epinephrine in a timely manner is a crucial factor in saving lives, given the practical challenges that may arise from the use of needles, most notably the hesitation associated with the fear of using them or the difficulty of taking them at critical moments .

EURneffy is easy to use and quick to apply, enabling immediate intervention even by untrained individuals. This simplicity reduces hesitation and accelerates response when symptoms appear, thus improving survival rates and health outcomes .

In this context, the Emirates Drug Foundation, during its recent visit to Denmark, learned about this innovation and worked with the manufacturer to accelerate its availability to patients in the UAE, thereby contributing to enhancing their safety and improving their quality of life by enabling them to quickly access life-saving treatment in critical moments.

This step comes as part of the Foundation’s ongoing efforts to strengthen the readiness of the health sector and expand the range of innovative treatment options, in line with global best practices and responding to the needs of patients in various emergency situations .

Her Excellency Dr. Fatima Al Kaabi, Director General of the Emirates Drug Authority, confirmed that the approval of this drug reflects the country’s strategic direction towards accelerating the adoption of therapeutic innovations that have a direct impact on patients’ lives. She said: “Making available advanced and easy-to-use therapeutic alternatives in critical cases is a priority, given their crucial role in improving the chances of response and reducing the risks associated with delays in therapeutic intervention . ”

Her Excellency added: “The registration of the first nasal adrenaline spray in the region in the UAE reflects the flexibility and efficiency of the regulatory system in the country, and its ability to attract and adopt innovative treatment solutions, which enhances the quality of healthcare and raises the level of preparedness in dealing with critical cases . ”

She explained that the Emirates Drug Authority is working to enable access to the latest treatments, through the development of advanced regulatory procedures that ensure rapid evaluation and accurate approval, which contributes to providing safe and effective treatment options that meet the needs of patients and enhance the sustainability of the health system .

Ghassan Al-Qutub, Regional General Manager at ALK-Abilo, said: “The registration of Urneve® represents an important step towards enhancing access for patients and healthcare providers to effective and easy-to-use treatment options in emergency situations.”

He added: “We are committed to providing innovative treatment solutions that meet patients’ needs in collaboration with our partners, and our cooperation with the Emirates Drug Foundation embodies a shared commitment to improving pharmaceutical care in the UAE and across the region.”

The adoption of this treatment confirms the UAE’s continued commitment to establishing itself as an advanced environment for adopting medical innovations, through a flexible regulatory system that balances the speed of making modern treatments available with ensuring the highest standards of quality and safety, which positively impacts community health and quality of life .

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.